Nab-paclitaxel: A novel formulation of taxane for treatment of breast cancer

Prakash Vishnu, Vivek Roy

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Breast cancer is the most common type of cancer diagnosed in women. Anthracyclines and taxanes are the most active and widely used chemotherapeutic agents in the treatment of both early-stage and advanced breast cancer. In the past decade, novel formulations of these cytotoxic agents have been developed to improve efficacy and decrease toxicity. nab-paclitaxel is a solvent-free, albumin-bound 130-nm particle form of paclitaxel (Abraxane ®, Abraxis Bioscience, CA, USA), which was developed to avoid toxicities associated with the Cremophor vehicle used in solvent-based paclitaxel. In a Phase III study, nab-paclitaxel demonstrated higher response rates, a better safety profile compared with conventional paclitaxel, and improved survival in patients receiving it as second-line therapy. Based on this pivotal trial, nab-paclitaxel is now approved in the USA for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant therapy where prior therapy included an anthracycline unless clinically contraindicated. Recently, several Phase II studies have suggested a role for nab-paclitaxel as a single agent and in combination with other agents for first-line treatment of metastatic breast cancer. Studies are ongoing to explore the use of nab-paclitaxel in other solid tumors such as non-small-cell lung cancer, ovarian cancer and malignant melanoma.

Original languageEnglish (US)
Pages (from-to)495-506
Number of pages12
JournalWomen's Health
Volume6
Issue number4
DOIs
StatePublished - Jul 1 2010

Fingerprint

Breast Neoplasms
Paclitaxel
Anthracyclines
Therapeutics
Taxoids
Cytotoxins
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Ovarian Neoplasms
taxane
130-nm albumin-bound paclitaxel
Albumins
Melanoma
Neoplasms
Safety
Recurrence
Survival

Keywords

  • docetaxel
  • metastatic breast cancer
  • nab-paclitaxel
  • nab-technology
  • paclitaxel
  • taxane

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nab-paclitaxel : A novel formulation of taxane for treatment of breast cancer. / Vishnu, Prakash; Roy, Vivek.

In: Women's Health, Vol. 6, No. 4, 01.07.2010, p. 495-506.

Research output: Contribution to journalReview article

@article{e9af929a1abb471ea53c97d49a0de5c2,
title = "Nab-paclitaxel: A novel formulation of taxane for treatment of breast cancer",
abstract = "Breast cancer is the most common type of cancer diagnosed in women. Anthracyclines and taxanes are the most active and widely used chemotherapeutic agents in the treatment of both early-stage and advanced breast cancer. In the past decade, novel formulations of these cytotoxic agents have been developed to improve efficacy and decrease toxicity. nab-paclitaxel is a solvent-free, albumin-bound 130-nm particle form of paclitaxel (Abraxane {\circledR}, Abraxis Bioscience, CA, USA), which was developed to avoid toxicities associated with the Cremophor vehicle used in solvent-based paclitaxel. In a Phase III study, nab-paclitaxel demonstrated higher response rates, a better safety profile compared with conventional paclitaxel, and improved survival in patients receiving it as second-line therapy. Based on this pivotal trial, nab-paclitaxel is now approved in the USA for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant therapy where prior therapy included an anthracycline unless clinically contraindicated. Recently, several Phase II studies have suggested a role for nab-paclitaxel as a single agent and in combination with other agents for first-line treatment of metastatic breast cancer. Studies are ongoing to explore the use of nab-paclitaxel in other solid tumors such as non-small-cell lung cancer, ovarian cancer and malignant melanoma.",
keywords = "docetaxel, metastatic breast cancer, nab-paclitaxel, nab-technology, paclitaxel, taxane",
author = "Prakash Vishnu and Vivek Roy",
year = "2010",
month = "7",
day = "1",
doi = "10.2217/whe.10.42",
language = "English (US)",
volume = "6",
pages = "495--506",
journal = "Women's health (London, England)",
issn = "1745-5065",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Nab-paclitaxel

T2 - A novel formulation of taxane for treatment of breast cancer

AU - Vishnu, Prakash

AU - Roy, Vivek

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Breast cancer is the most common type of cancer diagnosed in women. Anthracyclines and taxanes are the most active and widely used chemotherapeutic agents in the treatment of both early-stage and advanced breast cancer. In the past decade, novel formulations of these cytotoxic agents have been developed to improve efficacy and decrease toxicity. nab-paclitaxel is a solvent-free, albumin-bound 130-nm particle form of paclitaxel (Abraxane ®, Abraxis Bioscience, CA, USA), which was developed to avoid toxicities associated with the Cremophor vehicle used in solvent-based paclitaxel. In a Phase III study, nab-paclitaxel demonstrated higher response rates, a better safety profile compared with conventional paclitaxel, and improved survival in patients receiving it as second-line therapy. Based on this pivotal trial, nab-paclitaxel is now approved in the USA for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant therapy where prior therapy included an anthracycline unless clinically contraindicated. Recently, several Phase II studies have suggested a role for nab-paclitaxel as a single agent and in combination with other agents for first-line treatment of metastatic breast cancer. Studies are ongoing to explore the use of nab-paclitaxel in other solid tumors such as non-small-cell lung cancer, ovarian cancer and malignant melanoma.

AB - Breast cancer is the most common type of cancer diagnosed in women. Anthracyclines and taxanes are the most active and widely used chemotherapeutic agents in the treatment of both early-stage and advanced breast cancer. In the past decade, novel formulations of these cytotoxic agents have been developed to improve efficacy and decrease toxicity. nab-paclitaxel is a solvent-free, albumin-bound 130-nm particle form of paclitaxel (Abraxane ®, Abraxis Bioscience, CA, USA), which was developed to avoid toxicities associated with the Cremophor vehicle used in solvent-based paclitaxel. In a Phase III study, nab-paclitaxel demonstrated higher response rates, a better safety profile compared with conventional paclitaxel, and improved survival in patients receiving it as second-line therapy. Based on this pivotal trial, nab-paclitaxel is now approved in the USA for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant therapy where prior therapy included an anthracycline unless clinically contraindicated. Recently, several Phase II studies have suggested a role for nab-paclitaxel as a single agent and in combination with other agents for first-line treatment of metastatic breast cancer. Studies are ongoing to explore the use of nab-paclitaxel in other solid tumors such as non-small-cell lung cancer, ovarian cancer and malignant melanoma.

KW - docetaxel

KW - metastatic breast cancer

KW - nab-paclitaxel

KW - nab-technology

KW - paclitaxel

KW - taxane

UR - http://www.scopus.com/inward/record.url?scp=77954420212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954420212&partnerID=8YFLogxK

U2 - 10.2217/whe.10.42

DO - 10.2217/whe.10.42

M3 - Review article

C2 - 20597612

AN - SCOPUS:77954420212

VL - 6

SP - 495

EP - 506

JO - Women's health (London, England)

JF - Women's health (London, England)

SN - 1745-5065

IS - 4

ER -